十四烷基硫酸钠(Sodium Tetradecyl Sulfate)

概要

基本信息

药物类型

小分子化药

别名

7-Ethyl-2-methyl-4-undecanol sulfate sodium salt、7-ethyl-2-methyl-4-undecanolsulfate, sodium salt、Sodium 2-methyl-7-ethylundecanol-4-sulfate

+ [13]

靶点-

作用方式-

作用机制-

治疗领域

心血管疾病消化系统疾病

在研适应症-

非在研适应症

消化性溃疡静脉曲张

原研机构

Elkins-Sinn, Inc.

在研机构-

非在研机构

Elkins-Sinn, Inc.

最高研发阶段撤市

首次获批日期

美国 (1946-08-13),

消化性溃疡静脉曲张

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H30NaO4S

InChIKeyZNVVFVQLSXWPEV-UHFFFAOYSA-N

CAS号139-88-8

关联

15

项与十四烷基硫酸钠相关的临床试验

CTRI/2023/12/060776

/ Not yet recruiting临床4期IIT

Evaluation of foam sclerotherapy with sodium tetradecyl sulphate in periorbital dermoid cysts - NIL

开始日期2023-12-26

申办/合作机构-

CTRI/2023/08/056023

/ Not yet recruiting临床2期IIT

EVALUATION OF EFFICACY OF 3% SODIUM TETRADECYL SULPHATE AND 25% DEXTROSE IN THE TREATMENT OF TEMPOROMANDIBULAR JOINT HYPERMOBILITY -A DOUBLE BLINDED -RANDOMISED CLINICAL TRIAL - NIL

开始日期2023-08-24

申办/合作机构-

NCT05597995

/ Unknown status临床2期IIT

A Prospective Clinical Trial Evaluating the Efficacy of 1.5% Sodium Tetradecyl Sulfate Foam Injection for the Treatment of Epidermoid Cysts

The objective of this study is to determine the efficacy, safety, tolerability, and patient satisfaction associated with the treatment of epidermoid cysts with injected 1.5% sodium tetradecyl sulfate (STS) foam.

开始日期2022-11-01

申办/合作机构-

100 项与十四烷基硫酸钠相关的临床结果

登录后查看更多信息

100 项与十四烷基硫酸钠相关的转化医学

登录后查看更多信息

100 项与十四烷基硫酸钠相关的专利（医药）

登录后查看更多信息

573

项与十四烷基硫酸钠相关的文献（医药）

2025-07-01·Journal of Vascular Surgery-Venous and Lymphatic Disorders

Ultrasound-guided foam sclerotherapy of the saphenous trunks is associated with a low 5-year recurrence rate and improved quality of life in patients with chronic venous disease: A multicenter study

Article

作者: Massaroni, Rosaria ; Sozio, Giampaolo ; Bianchi, Valerio ; Bucalossi, Matteo ; Andreucci, Eleonora ; Mariani, Fabrizio ; Carbone, Ludovico

OBJECTIVE:

The study attempts to test whether ultrasound-guided foam sclerotherapy (UGFS) is a durable treatment for incompetent great saphenous vein (GSV) and incompetent small saphenous vein (SSV) in primary chronic venous disease (CVD), Clinical-Etiology-Anatomy-Pathophysiology (CEAP) clinical grade 2 to 4 disease. Secondary end points are to evaluate its safety in terms of complications, to compare patients' quality of life before and after the treatment, and to identify risk factors that may predict recurrence of CVD after UGFS.

METHODS:

Multicenter retrospective cohort study on 346 patients. The sclerosing agent was sodium tetradecyl sulfate (STS) in foam. The foam was prepared with the double-syringe technique (liquid-to-gas CO₂O_{2 30:70} ratio of 1:4). The sclerosing agent concentrations were 1% for saphenous trunk diameter 4 to 7 mm, 3% for saphenous trunk of >7 mm. Sodium tetradecyl sulfate was injected directly into the GSV/SSV, achieving a total maximum volume of 10 mL per session. A median of two sessions was performed (range, 1-5).

RESULTS:

In this cohort, 205 patients were categorized as CEAP C2 (59.2%), and 141 (40.8%) had worse CVD (CEAP ≥3). The median follow-up was 60 months (range, 6-60 months). At the end of follow-up, 296 patients (85.5%) had no truncal reflux, with a 5-year disease-free time (between last procedure and evidence of recurrent disease) of 77.7 ± 2.16%. GSV and SSV showed similar 5-year recurrence-free time rates (69.9% vs 76.8%; P = ns), whereas patients with a diameter of the saphenous trunk of ≤8 mm had lower recurrence than those with >8 mm (91.3% vs 46%; P < .0001). Ninety patients (26%) showed CVD recurrence, occurring at a median of 48 months. A further UGFS treatment was needed in 50 symptomatic patients (14.4%), resulting in an 80% success rate. At univariate analysis, large diameter of the saphenous trunk (P < .0001), male sex (P = .030) and greater number of treatment sessions (P = .009) were identified as significant prognostic factors for recurrence. Immediate complications occurred in 3.7% of patients: seven headache and six visual disturbances. Endovenous foam-induced thrombosis was detected in six patients (2.8%) 1 week after treatment. Cutaneous hyperpigmentation appeared in 37 patients (10.7%). Post-treatment revised Venous Clinical Severity Score and Chronic Venous Disease Quality of Life Questionnaire 14 scores were significantly lower than before treatment (P < .001).

CONCLUSIONS:

UGFS of the GSV/SSV is effective, safe in the long term and well-accepted by patients. UGFS is a viable option to surgery and endovenous thermal or nonthermal ablation in the treatment of saphenous trunk incompetence (CEAP clinical grade 2-4).

2025-01-01·AMERICAN JOURNAL OF OTOLARYNGOLOGY

Treatment of hereditary hemorrhagic telangiectasias with sclerotherapy: A case series

Article

作者: Piccirillo, Jay F ; Ji, Jenny ; Peterson, Andrew M

BACKGROUND:

Hereditary hemorrhagic telangiectasia (HHT) is characterized by abnormal blood vessel formation. One treatment for HHT-related arteriovenous malformations (AVMs) is sclerotherapy, which collapses the blood vessels by irritating the endothelial lining.

METHODS:

This case series describes two HHT patients undergoing in-office sodium tetradecyl sulfate sclerotherapy for non-nasal telangiectasias and AVMs. The first patient had AVMs on the red lip while the second patient had an AVM and several telangiectasias on the tongue.

RESULTS:

Both patients' AVMs required only one treatment visit and were no longer noticeable within a week. Neither of the patients had any side effects from treatment.

CONCLUSION:

Sclerotherapy was used to successfully treat HHT-related AVMs in-office with no scarring and is an option that should be considered by providers.

2024-11-01·JOURNAL OF MOLECULAR LIQUIDS

Diamine-surfactant adsorption at the air–water interface: The impact of the diamine structure, surfactant structure and solution pH

作者: Penfold, J. ; Webster, J.R.P. ; Chen, Y. ; Ma, K. ; Wang, Z. ; Li, P.X. ; Thomas, R.K. ; Li, P. X. ; Campana, M. ; Penfold, J ; Webster, J. R. P. ; Thomas, R. K.

The biogenic amines, polyamines, such as putrescine and cadavarine, are small flexible polycations.They interact with charged biol. species and have a range of important biol. functions.Their strong interaction with anionic surfactants results in enhanced adsorption at interfaces.Aspects of the impact of the polyamine mol. weight and structure on the pattern of surfactant adsorption at the air-water interface have been explored previously using neutron reflectivity, NR, and surface tension, ST.However there is limited evidence for the extent to which surfactant adsorption can be manipulated and the impact of the diamine structure and surfactant headgroup structure on surfactant adsorption at the air-water interface is reported here.The addition of putrescine [1,4 diaminobutane or butanediamine] over the pH range 3 to 10 enhances significantly the adsorption of sodium dodecyl sulfate, SDS, sodium dodecyl diethylene sulfate, SLES, and sodium tetradecyl Me ester sulfonate, MES.For SDS and to a lesser extent MES there are regions where surface multilayer adsorption occurs at both pH 3 and 10, and this extends significantly the range of polyamine structures for which this is observedModifying the diamine spacer with ethylene oxide groups of varying length still results in enhanced adsorption for SDS and MES, but the enhancement is less pronounced and depends upon the size of the ethylene oxide group.However the incorporation of the ethylene oxide group does suppresses the formation of the more complex surface multilayered structures.

1

项与十四烷基硫酸钠相关的新闻（医药）

2024-12-12

·上海医药

上海医药十四烷基硫酸钠注射液获得临床试验批准通知书

近日，上海医药全资子公司上海上药第一生化药业有限公司收到国家药品监督管理局核准签发的关于十四烷基硫酸钠注射液的《药物临床试验批准通知书》（通知书编号：2024LP02466、2024LP02467），将于近期启动Ⅰ期临床试验。药物名称十四烷基硫酸钠注射液剂型注射剂申请事项境内生产药品注册临床试验申报受理号 CYHL2400166、CYHL2400167 通知书编号 2024LP02466、2024LP02467 结论根据《中华人民共和国药品管理法》及有关规定，经审查，十四烷基硫酸钠注射液符合药品注册的有关要求，同意本品开展临床试验。相关信息十四烷基硫酸钠是一种硬化剂，拟用于治疗无并发症的原发性下肢浅静脉曲张、术后复发或残留的静脉曲张及简单扩张的下肢网状静脉，小静脉和蜘蛛状静脉。十四烷基硫酸钠注射后化学刺激性小，不产生剧烈疼痛，无醉酒样反应等，具有疗效确切、安全性好等优势。该项目由上药第一生化自主研发，并拥有完全知识产权，截至目前，国内尚无十四烷基硫酸钠注射液获批上市。2024年8月，该项目的临床试验申请获得国家药监局正式受理，近日，该项目获得国家药监局核准签发《药物临床试验批准通知书》，同意按照已提交的方案开展临床试验。 IQVIA数据库显示，2023年同类适应症药物的国内医院采购金额为人民币41,806万元。

临床1期申请上市

100 项与十四烷基硫酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06882	十四烷基硫酸钠	C05BB04	DB00464

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
消化性溃疡	美国	Elkins-Sinn, Inc.	1946-08-13
静脉曲张	美国	Elkins-Sinn, Inc.	1946-08-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	N/A	化脓性肉芽肿	18	Intralesional STDS 1%	窪糧鬱壓遞鬱壓憲夢艱(網積獵衊鬱憲廠膚獵鹹) = 鬱鏇齋衊醖醖簾膚窪鑰齋夢鹹夢獵鏇齋築製憲 (艱鬱鹹簾壓淵構網憲願 )	积极	2023-07-07
AUA2022	N/A	睾丸鞘膜积液	176	sodium tetradecyl sulphate (Aspiration alone)	簾鬱鏇淵顧繭鏇齋選艱(範淵鹽艱壓顧憲選繭齋) = 憲鑰衊衊觸淵鹹淵蓋遞選簾淵獵糧廠顧廠糧獵 (顧艱醖蓋襯範壓夢鹹餘 ) 更多	-	2022-05-01
				Ethanol sclerosed	簾鬱鏇淵顧繭鏇齋選艱(範淵鹽艱壓顧憲選繭齋) = 鏇遞簾繭壓顧鹹醖觸醖選簾淵獵糧廠顧廠糧獵 (顧艱醖蓋襯範壓夢鹹餘 ) 更多
NCT03311269 (VICARES, CTgov)	临床2期	静脉功能不全	19	ClariVein RES+Sodium Tetradecyl Sulfate 1% Injection (ClariVein RES 1% Injection)	鏇鏇鏇齋鏇獵餘鹽衊膚(鑰願淵選憲觸網範廠築) = 鬱繭餘廠淵簾襯鏇簾製鑰衊窪壓遞窪廠構築選 (鹹網壓壓鑰廠衊網鬱艱, 3.00) 更多	-	2022-03-02
				ClariVein RES+Sodium Tetradecyl Sulfate 3% Injection (ClariVein RES 3% Injection)	鏇鏇鏇齋鏇獵餘鹽衊膚(鑰願淵選憲觸網範廠築) = 顧膚膚夢夢齋鏇膚廠遞鑰衊窪壓遞窪廠構築選 (鹹網壓壓鑰廠衊網鬱艱, 1.87) 更多
NCT03363633 (Dillavou, CTgov)	N/A	静脉血管疾病	12	sodium tetradecyl sulfate	鹹鬱積製簾觸醖獵鏇淵(餘構醖膚醖襯願選築鏇) = 選範鬱製夢繭餘夢鏇夢觸積醖積鏇壓顧鏇繭鏇 (繭獵糧簾積齋築願網遞, 獵遞鹹窪鑰醖構蓋顧糧 ~ 襯顧顧鹹鏇鬱夢醖衊糧) 更多	-	2018-02-23
SIOPEL 6 (AACR2016)	临床3期	肝母细胞瘤	37	Cisplatin + Sodium Thiosulphate (STS)	夢廠鑰鏇範廠餘遞襯艱(齋繭選襯淵鹽製糧壓觸) = 糧網憲鬱積餘簾範選選願遞鏇選窪繭膚範艱齋 (鹽壓餘簾築構鏇簾願鏇 )	-	2016-07-15
				Cisplatin alone	夢廠鑰鏇範廠餘遞襯艱(齋繭選襯淵鹽製糧壓觸) = 壓範構壓繭襯糧艱簾廠願遞鏇選窪繭膚範艱齋 (鹽壓餘簾築構鏇簾願鏇 )
EASI study (Pubmed \| Phlebology)	N/A	毛细血管扩张	316	Polidocanol 0.5%	淵蓋衊製積夢夢鹹膚餘(憲觸醖夢鑰範鹽鬱鹽鹽) = 鬱夢鏇築顧簾夢膚獵鹽糧鬱構繭選鏇觸夢鹽廠 (壓鑰獵積鏇餘顧簾鏇鏇 )	积极	2010-06-01
				Sodium tetradecyl sulphate 1%	淵蓋衊製積夢夢鹹膚餘(憲觸醖夢鑰範鹽鬱鹽鹽) = 窪顧膚願淵鬱製衊範糧糧鬱構繭選鏇觸夢鹽廠 (壓鑰獵積鏇餘顧簾鏇鏇 )